Chiesi has announced the initiation of a Phase 3 safety study of CHF5993 beclometasone / formoterol / glycopyrronium HFA 152a MDI, an LGWP propellant version of Trimbow MDI, which uses HFA 134a as a propellant. In December 2019, Chiesi announced that it planned to bring an HFA 152a inhaler to market by the end of 2025.
The Phase 3 trial will compare the HFA 152a formulation with the HFA 134a formulation in subjects with moderate-to-severe asthma. According to the study record, the anticipated completion date is in September 2025.
Chiesi Group CEO Giuseppe Accogli commented, “At Chiesi, we strongly believe that patients should not have to bear the responsibility of environmental impact when considering treatment options that affect their health. The conclusion of these additional studies and the start of the Phase 3 trial mark a significant milestone in our development of a new carbon minimal inhalers platform. We are confident that we can deliver carbon minimal solutions to patients without compromising safety, usability or efficacy.”
Read the Chiesi press release.
